{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:53:08Z","timestamp":1790949188533,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We conducted a post hoc analysis of data from Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO), a randomized trial of gilteritinib vs placebo as posttransplantation maintenance for patients with FLT3-ITD\u2013mutated acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT), focusing the interactions between conditioning regimen intensity, measurable residual disease (MRD), and NPM1 comutation status reported from diagnosis. Comparing FLT3-ITD MRD before and after conditioning, there was no difference between myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in eradication or reduction of FLT3-ITD MRD. For participants who were FLT3-ITD MRD negative before HCT, there was no difference in the cumulative incidence of relapse during follow-up between those receiving MAC vs RIC. NPM1 comutation was associated with the largest magnitude of relapse-free survival benefit from post-HCT gilteritinib, and in these participants, post-HCT gilteritinib in the setting of RIC appeared to be as effective as MAC at preventing relapse. MAC appeared superior to RIC in preventing relapse only in participants who were NPM1 wild type at diagnosis and FLT3-ITD MRD positive before HCT. Our findings suggest that only a subset of patients with FLT3-ITD AML undergoing HCT may benefit from MAC and that, similar to AML therapy before HCT, the intensity of the HCT regimen should be adapted according to the molecular features of the disease. This trial was registered at www.clinicaltrials.gov as #NCT02997202.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016306","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:51:02Z","timestamp":1751367062000},"page":"5123-5133","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Impact of transplant conditioning,\n                    <i>NPM1<\/i>\n                    mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark J.","family":"Levis","sequence":"first","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplant, Department of Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Center for International Blood and Marrow Transplant Research\/Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent R.","family":"Logan","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Center for International Blood and Marrow Transplant Research\/Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Bone Marrow Transplant, Department of Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[{"name":"3Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Transplant Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-1861","authenticated-orcid":false,"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"7Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"8Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-6213","authenticated-orcid":false,"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"9Division of Hematology Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1976","authenticated-orcid":false,"given":"Masumi Ueda","family":"Oshima","sequence":"additional","affiliation":[{"name":"10Cancer Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6729","authenticated-orcid":false,"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"13Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"14Bone Marrow Transplant, Acute Leukemia, and Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Mishra","sequence":"additional","affiliation":[{"name":"15Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"16Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"17Catholic Hematology Hospital, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"18Department of Medicine\/Hematology and Oncology, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[{"name":"19Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Onozawa","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Thomson","sequence":"additional","affiliation":[{"name":"21Department of Hematology, University College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chen","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Hasabou","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Rosales","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-1661","authenticated-orcid":false,"given":"Jason E.","family":"Hill","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C.","family":"Gill","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishita","family":"Nuthethi","sequence":"additional","affiliation":[{"name":"22Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"King","sequence":"additional","affiliation":[{"name":"23The Emmes Company, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mendizabal","sequence":"additional","affiliation":[{"name":"23The Emmes Company, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[{"name":"24National Marrow Donor Program, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Center for International Blood and Marrow Transplant Research\/Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"25Department of Hematology\/Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025102809014950900_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?","volume":"2013","author":"Levis","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"2025102809014950900_bib2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025102809014950900_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025102809014950900_bib4","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"key":"2025102809014950900_bib5","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.26.23287367","article-title":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","author":"Dillon","year":"27  2023","journal-title":"medRxiv"},{"issue":"15","key":"2025102809014950900_bib6","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025102809014950900_bib7","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"19","key":"2025102809014950900_bib8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025102809014950900_bib9","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2025102809014950900_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2025102809014950900_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"2025102809014950900_bib12","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025102809014950900_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025102809014950900_bib14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan vs fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"issue":"13","key":"2025102809014950900_bib15","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/bloodadvances.2019001266","article-title":"Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report","volume":"4","author":"Zhou","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2025102809014950900_bib16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2025102809014950900_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2025102809014950900_bib18","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2025102809014950900_bib19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2025102809014950900_bib20","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025102809014950900_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00277-002-0535-7","article-title":"Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy","volume":"81","author":"Bojko","year":"2002","journal-title":"Ann Hematol"},{"issue":"26","key":"2025102809014950900_bib22","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","article-title":"FLT3\/ITD AML and the law of unintended consequences","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2025102809014950900_bib23","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025102809014950900_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","article-title":"Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results","volume":"36","author":"R\u00fccker","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"2025102809014950900_bib25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov"},{"issue":"7","key":"2025102809014950900_bib26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2025102809014950900_bib27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5123\/2416680\/blooda_adv-2025-016306-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5123\/2416680\/blooda_adv-2025-016306-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:01:58Z","timestamp":1761656518000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5123\/538038\/Impact-of-transplant-conditioning-NPM1-mutations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":27,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016306","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,15]]}}}